The company said the FDA had accepted its application for accelerated approval of Tazverik in relapsed/refractory follicular lymphoma. The drug won accelerated approval last month for epithelioid sarcoma.
The agency gave accelerated approval to Tazverik in epithelioid sarcoma, a rare but serious connective tissue cancer. The company is also seeking approval for the drug, an EZH2 inhibitor, for the blood cancer follicular lymphoma.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The agency's Oncologic Drugs Advisory Committee voted unanimously to recommend approval of tazemetostat for epithelioid sarcoma. The company has said it would likely use drugs like Bristol-Myers Squibb's Revlimid as a benchmark for pricing.
The company said Thursday the agency had accepted its accelerated approval application for tazemetostat in epithelioid sarcoma. An analyst wrote that an FDA advisory committee meeting is likely to happen in the fourth quarter.